drugset / Trial / NCT05018728

The Effect of Voxelotor on Cerebral Hemodynamic Response in Children With Sickle Cell Anemia

NCT05018728

Phase 2 Terminated 22 enrolled Emory University Pfizer · collab
NaSingle-groupOpen-labelSupportive care

Summary

Voxelotor is a new drug for adolescents and adults with sickle cell disease that improves hemoglobin levels and reduces the incidence of worsening anemia. However, it is unclear whether this increase in hemoglobin is associated with a reduction in cerebral metabolic stress. This study will measure the effects of voxelotor on cerebral hemodynamics.

Timeline

Start
2022-03-28
Primary completion
2024-10-22
Completion
2024-10-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Voxelotor Small molecule 1500 mg Oral

Indications